Innovent and Eli Lilly will jointly announce final clinical results and biomarker analysis of the Phase Ib study of Dabosu (sintilimab injection) combined with bevacizumab in the treatment of advanced hepatocellular carcinoma at ASCO GI in 2022 result

Lilly Wang, Senior Vice President of China and Head of Drug Development and Medical Affairs Center, said: "The collaboration between Eli Lilly and Innovent is ^committed to bringing anti-tumor drugs of international quality to Chinese cancer patients

About the NCT04072679 study

NCT04072679 is a Phase Ib study evaluating the safety, tolerability and antitumor activity of Dabosu® in ^combination with bevacizumab in subjects with advanced hepatocellular carcinoma

About liver cancer

Liver cancer is a common malignant tumor of the digestive system in the world.

About sintilimab

Sintilimab, with Chinese trade name Daboshu® ⁽ sintilimab injection), is an innovative PD-1 inhibitor drug with international quality jointly developed by Innovent Biopharmaceuticals and Eli Lilly

Sintilimab has been approved in China for four indications and has been successfully included in China's National Medical Insurance List, including:

• For the treatment of relapsed or refractory classical Hodgkin lymphoma that has undergone at least second-line systemic chemotherapy;
• Combination of pemetrexed and platinum-based chemotherapy for first-line treatment of EGFR- or ALK-negative advanced non-squamous NSCLC;
• Combined with gemcitabine and platinum-based chemotherapy for the first-line treatment of unresectable locally advanced or metastatic squamous NSCLC;
• Combined with bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy
  
  
  • Combination of cisplatin and paclitaxel/cisplatin and 5-fluorouracil for first-line treatment of advanced or metastatic esophageal squamous cell carcinoma;
  • Combination of oxaliplatin and capecitabine in the first-line treatment of unresectable locally advanced, recurrent or metastatic gastric and gastroesophageal junction adenocarcinoma;
  • Combination of bevacizumab and chemotherapy for epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-failed EGFR-mutant non-squamous non-small cell lung cancer
    
    
    • Phase II clinical study of single drug for second-line treatment of advanced/metastatic esophageal squamous cell carcinoma;
    • Phase III clinical study of single agent for second-line treatment of advanced squamous non-small cell lung cancer failed platinum-containing chemotherapy
      
      

      About Dayoton® ( bevacizumab)

      Dayutong® is a ^biosimilar drug of bevacizumab injection, also known as recombinant anti-VEGF humanized monoclonal antibody injection

      
      

      About Innovent

      "Begins with faith, achieves in action", and developing high-quality biological drugs affordable to the common people is the ideal and goal of Innovent

      
      

      Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model

      
      

      Innovent Bio has established a high-end biopharmaceutical development and industrialization talent team with international advanced level, including many returnee experts, and has cooperated with international partners such as Eli Lilly, Adimab, Incyte, MD Anderson Cancer Center and Hanmi in South Korea.

      
      

      About Eli Lilly

      Eli Lilly is a leading global pharmaceutical company dedicated to improving human health through innovation
      .
      Eli Lilly was born more than a century ago, with founders dedicated to producing high-quality medicines to meet real medical needs
      .
      Today, we remain committed to this mission and work based on it
      .
      Across the globe, our employees work hard to develop life-changing medicines and bring them to those patients who really need them
      .
      Not only that, but we are also committed to improving public understanding and management of disease, while giving back to society through our philanthropy and volunteer activities
      .
      For more information about Lilly, please visit: .
      

      About the strategic cooperation between Eli Lilly and Innovent

      Eli Lilly and Innovent reached a biotech drug development cooperation in March 2015, which is also one of the largest cooperation between a Chinese biopharmaceutical company and a multinational pharmaceutical company to date
      .
      Under the terms of the partnership, Eli Lilly and Innovent will co-develop and commercialize oncology drugs including Dabosu® ( ^sintilimab injection) in China
      .
      In October 2015, the two parties announced that they would once again expand their established drug development collaboration, adding three novel oncology therapeutic antibodies
      .
      In August 2019, the collaboration between the two parties was extended to the field of diabetes, and Innovent was authorized to develop and commercialize a potentially best-in-class new clinical-stage diabetes drug from Eli Lilly in China
      .
      These three collaborations with Eli Lilly signify that Innovent Bio has established a comprehensive strategic partnership between Chinese innovative pharmaceutical companies and global pharmaceutical giants, covering new drug research and development, clinical research, production quality and market sales
      .
      

      Disclaimer:
      For communication use by healthcare professionals only
      .
      

      Innovent Forward-Looking Statements

      Information published in this press release may contain certain forward-looking statements
      .
      These statements are inherently subject to considerable risk and uncertainty
      .
      The use of words such as "anticipates," "believes," "forecasts," "expects," "intends," and other similar words in relation to the Company is intended to identify forward-looking statements
      .
      The Company undertakes no obligation to continually update these forward-looking statements
      .
      

      These forward-looking statements are based on the Company's management's current beliefs, assumptions, expectations, estimates, projections and understanding of future events at the time the statements are made
      .
      These statements are not guarantees for future development and are subject to risks, uncertainties and other factors, some of which are beyond the control of the company and are difficult to predict
      .
      Accordingly, actual results may differ materially from those contained in forward-looking statements as a result of future changes and developments in our business, competitive environment, political, economic, legal and social conditions
      .
      

      The Company, its directors and employee agents disclaim (a) any obligation to correct or update the forward-looking statements contained in this website; and (b) any responsibility
      .